Meu SciELO
Serviços Personalizados
Artigo
Indicadores
Citado por SciELO
Links relacionados
Similares em SciELO
Compartilhar
Revista Cubana de Hematología, Inmunología y Hemoterapia
versão On-line ISSN 1561-2996
Resumo
HERNANDEZ CRUZ, Calixto et al. Autologous stem cell transplantation in monoclonal gammopathies: first results from the “Hermanos Ameijeiras” Hospital. Rev Cubana Hematol Inmunol Hemoter [online]. 2019, vol.35, n.4 Epub 20-Fev-2020. ISSN 1561-2996.
Introduction:
The recent advances in the management of multiple myeloma (MM) during the last years have included the autologous hematopoietic stem cell transplantation (auto-HSCT) to the treatment strategy of these patients.
Objective:
To present the first results in the "Hermanos Ameijeiras" hospital (HAH) with the application of auto-HSCT in patients with monoclonal gammopathies (MG) using high doses of melphalan (HD-Mel) as conditioning regimen (CR) and its impacton overall survival (OS).
Methods:
A retrospective study of all patients with MG who underwent auto-HSCT in the Hematology Service of the HAH in the period between 2009 and 2018 wasmade. The final sample comprised 14 cases.
Results:
The average age was 53.5 years; the majority had diagnosis of MM (85.7%) and all of them were diagnosed in stage III of Durie-Salmon; as CR 64.2% received HD-mel, at 200 mg/m2. The recovery of neutrophil and platelet counts occurred on average at 11.4 and 12 days respectively. Transplant related mortality (TRM) at day +30 was 7.1%. The probability of OS at 2 years was higher than 90% and at 5 years of 68%.
Conclusions:
It was verified that the performance of auto-HSCT with the use of HD-Mel as CR in patients with MG is a feasible procedure in our country with a relatively low TRM. It was possible to demonstrate that the inclusion of auto-HSCT in the treatment considerably improves the survival expectations of these patients.
Palavras-chave : autologous stem cell transplant; multiple myeloma; high doses of melphalan.